Hepatitis C Virus Therapy

Reports from University of Barcelona advance knowledge in hepatitis C virus therapy

Published in Hepatitis Weekly, June 18th, 2007

Data detailed in "Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study" have been presented. "Recurrence of hepatitis C virus (HCV) infection is a relevant problem of liver transplantation programs. We evaluated the effect of antiviral therapy on disease progression in 81 HCV-infected liver transplantation recipients," investigators in Barcelona, Spain report.

"Patients with mild hepatitis C recurrence (fibrosis stage F0 to F2, n=54) were randomized to no treatment (group A, n=27) or peginterferon alfa-2b/ribavirin for 48 weeks (group B, n=27). Patients with severe recurrence (F3 to F4, cholestatic hepatitis)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2007-06-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry